MANAGING CHRONIC PAIN IN DOGS & CATS
Part 2: The Best of the Rest in the Management of Osteoarthritis

Mark E. Epstein, DVM, Diplomate ABVP (Canine/Feline), CVPP
Carolinias Animal Pain Management & TotalBond Animal Hospitals (Forestbrook), Gastonia, North Carolina

Part 1—The Two Most Important Tools in the Management of Osteoarthritis (November/December 2013, available at tvpjournal.com)—of this 3-part series addressed basic principles of chronic pain and also discussed treatment for its most common manifestation in companion animals: osteoarthritis (OA).

While Part 1 dealt with the 2 most important considerations in OA therapy: weight optimization and nonsteroidal anti-inflammatory drug (NSAID) therapy, this article discusses other modalities—both pharmacologic and nonpharmacologic—for treatment of canine and feline OA.

TOP 3 MODALITIES
Well-designed, systematic reviews evaluating treatment of OA and nonsurgical management of hip dysplasia in dogs are now available.1,2 Very good review articles are also available for cats diagnosed with OA.3

Based on these evidence-based perspectives—once weight optimization and NSAID therapy have been implemented—3 modalities rise to the top of the list.

1. Polysulfated Glycosaminoglycans
Veterinary polysulfated glycosaminoglycans (PSGAGs) administered by the parenteral route (ie, IM injection) have met both regulatory scrutiny and quality control measures; independent studies appear to support their clinical utility.4,5 Examples include (Table 1):

- PSGAG (Adequan Canine, novartis.com)
- Sodium pentosan polysulfate (Cartrophen Vet for Dogs, biopharmaus.com.au).

In contrast, clinical evidence for oral nutraceuticals is limited in dogs and cats and, at best, conflicting in humans. However, it can be argued that initiating use of oral nutraceuticals early in life, particularly for at-risk breeds, is safe and may provide some long-term chondro-protective effect.

- If nutraceuticals and oral supplements are used, caution is warranted due to the following concerns:
  - Degree of quality control
  - Potential drug interactions, especially with NSAIDs, because some over-the-counter products contain aspirin or other cyclooxygenase (COX)-inhibiting agents
  - Ingredients derived from endangered species
  - Need for clinical studies to demonstrate efficacy.

2. Omega-3 Fatty Acids
Several randomized placebo-controlled blinded studies6-10 and one systematic review11 have demonstrated the efficacy of diets rich in:

- Eicosapentaenoic acid (EPA) for dogs with OA
- Docosahexaenoic acid (DHA) for cats with OA.

The availability of multiple randomized placebo-controlled blinded studies and systematic reviews place these data high on the evidence-based pyramid. However, this type of supplementation should be reserved for pets at a healthy weight.

<table>
<thead>
<tr>
<th>TABLE 1. On- and Off-Label Use of Polysulfated Glycosaminoglycans</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>On-Label Dose: Dogs</strong></td>
</tr>
<tr>
<td>Adequan</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Cartrophen Vet</td>
</tr>
</tbody>
</table>
3. Therapeutic Exercise
While a relatively new modality in veterinary medicine, controlled, prescribed exercise is well established in humans for amelioration of pain related to OA. There is every reason to believe that dogs and cats can benefit as well due to a variety of mechanisms, including:
- The Gate Theory of pain
- Activation of endogenous opioids
- Enhanced strength of periarticular soft tissue (eg, muscle, tendon, ligament) and resulting improved microstability of joints
- Weight loss (if needed).

Some studies already support use of this modality in painful dogs with OA. 14,15

ADDITIONAL OPTIONS
The evidence for other recommended treatments for OA pain is either limited, weak, conflicting, or based on in vitro cellular/molecular rather than clinical data. However, modalities that may play a role in management of OA in dogs and cats include:
- Pharmacologic (pain modifying analgesic drugs)
- Nonpharmacologic
- Biologic.

Pharmacologic Therapy Options (Table 2, page 29)

Gabapentin
No clinical studies evaluating gabapentin—as a single agent or an adjunct to NSAIDs—for the treatment of OA have been conducted in humans, dogs, or cats. However, a neuropharmacologic rationale exists for gabapentin’s ability to diminish central and peripheral sensitization, which is supported by a number of rodent studies.17,18

One canine study suggests that gabapentin may provide a chondroprotective effect in experimentally induced OA,19 and a pending study in cats appears to demonstrate the clinical efficacy of gabapentin for pain associated with naturally occurring feline hip OA. 20

**Gate Theory of Pain**
The spinal cord has a functional, neurophysiologic “gate” that can either block or allow pain signaling to the brain;16 by sending other signals to the brain during exercise (eg, proprioception), pain signaling through the spinal cord “gate” is, to a degree, blocked.

**Macrostability:** Gross subluxation
**Microstability:** Diminished laxity of joint that cannot be grossly appreciated
**Amantadine**

One study in dogs with refractory OA demonstrated the efficacy of amantadine and an NSAID versus NSAIDs alone.\(^{21}\)

**Tramadol**

The pharmacokinetics of oral tramadol do not favor its use for OA pain in dogs.\(^{22-25}\) In fact, the pharmacokinetics of oral tramadol are not favorable in the dog, in general, and especially not for chronic use (plasma levels, low to begin with, diminish rapidly to near negligible levels after sequential use over several days). Even with IV tramadol, dogs do not produce the mu receptor active metabolite that occurs in humans.\(^{26}\) It may be better suited pharmacologically for cats,\(^{27}\) but its extremely bitter taste may limit its use.

At this time, no studies have been published that demonstrate tramadol’s efficacy for treatment of OA in cats or dogs, either alone or as an adjunct to NSAIDs. The results of one canine study suggested that dogs with OA improved with tramadol according to owner assessments; however, the placebo group also improved, and there was no improvement in the tramadol group according to objective gait analysis.\(^{28}\) However, one study submitted for publication may reveal more encouraging results.\(^{29}\)

**The Role of Constant Rate Infusions**

Intravenous constant rate infusions (CRI) of ketamine, lidocaine, opioids, or a combination can be used for a 24 to 48 hour pain holiday and to also reduce central sensitization. Used for severe neuro-pathic pain states in humans, this methodology has been anecdotally used but not yet investigated in canine and feline patients with OA.

**Tricyclic Antidepressants & Selective Serotonin/Norepinephrine Reuptake Inhibitors**

Although known for their ability to treat chronic and neuropathic pain conditions in humans, as of yet, no data support the use of these drugs for management of canine or feline OA.

- Duloxetine (Cymbalta, lilly.com), a selective serotonin/norepinephrine reuptake inhibitor, is labeled for musculoskeletal and low back pain in humans, but has very poor oral bioavailability in dogs.\(^{29}\)

- Oral venlafaxine (Effexor, pfizer.com), labeled as an antidepressant in humans, has been demonstrated to diminish pain intensity and improve function in humans with OA.\(^{30}\) In dogs, it has approximately 50% bioavailability and a half-life of 3 hours.\(^ {31}\)

- There is no strong evidence for the pain modifying effect of fluoxetine, a selective serotonin reuptake inhibitor.

**Corticosteroids**

Intra-articular corticosteroid injection is a first-line therapy for OA in humans and horses. In dogs, studies in experimentally induced OA demonstrate that corticosteroid injections may have a disease modifying and, possibly, chondro-protective effect,\(^{32-35}\) but clinical studies are lacking.

**Acetaminophen**

Acetaminophen remains a first-line therapy for acute and chronic pain in elderly humans,\(^{36}\) and unlike cats, a literature search for toxicity in dogs does not reveal any special sensitivity to adverse effects or toxicity in this species. Judicious use can be considered in dogs but not in cats.

**Oral Opioids**

Dogs have a robust first-pass effect with oral opioids, limiting their usefulness compared with human patients, but pharmacokinetic studies reveal the possible efficacy of codeine\(^{37}\) and hydrocodone\(^ {38}\) in this species.

**Nonpharmacologic**

Nonpharmacologic treatment of OA in dogs and cats includes a variety of therapies (Table 3, page 29). While unsupported at this time by strong clinical evidence, these modalities:

- Have plausible, if yet unproven, beneficial effects
- Are generally safe with proper use
- May be employed as an adjunct to other therapies, or when nonpharmacologic modalities are indicated or preferred.

As part of an integrated approach to treating pain, acupuncture, in particular, has been accepted by both the National Institutes of Health (nih.gov) and International Veterinary Academy of Pain Management (ivapm.org) in their respective position/consensus statements.

**Biologic**

The relative merits and roles of intra-articular stem cell therapy, platelet-rich plasma therapy, extracellular matrix bioscaffolds, hyaluronate, and even botulinum toxin remain areas of interest and research. How these modalities will fit into management of OA remains undetermined at this time.

One commercial autologous conditioned serum product (IRAP, arthrexvetsystems.com) is labeled for intra-articu-
TABLE 2. Recommended Doses for Pain Modifying Analgesic Drugs

<table>
<thead>
<tr>
<th>Pain Modifying Analgesic Drugs</th>
<th>SUGGESTED DOSE</th>
<th>PRIMARY ADVERSE EFFECTS &amp; NOTES</th>
</tr>
</thead>
</table>
| Acetaminophen                    | 10–15 mg/kg PO Q 12 H³⁹ | • Contraindicated in cats  
• No special proclivity toward hepatotoxicity in dogs; judicious use recommended |
| Amantadine (NMDA receptor antagonist) | 3–5 mg/kg PO Q 12 H²¹ | • Primary adverse effects include agitation and diarrhea  
• Anticholinergic |
| Amitriptyline* (Tricyclic antidepressant) | Dogs, initial dose: 1–2 mg/kg PO Q 8–12 H²⁹  
Increase as needed to: 3–4 mg/kg PO Q 8–12 H²⁹ | • Primary adverse effects include, in humans, dry mouth, sedation, behavioral changes, and seizure potentiation |
| Codeine* (Opioid) | 0.5–2 mg/kg PO Q 12 H³⁹ | • Some suggest dogs only  
• Pharmacokinetics, but no clinical data, available |
| Gabapentin (Anticonvulsant) | Initially 3–5 mg/kg PO Q 12 H, taper upwards to effect; doses as high as 20 mg/kg or more may be needed PO Q 8–12 H³⁹ | • Primary adverse effects include somnolence, which can be minimized by starting with lower doses and gradually increasing to effect  
• For smaller animals, may be compounded into 50 mg/mL nonxylitol containing suspension |
| Hydrocodone* (Opioid) | 0.22–0.5 mg/kg PO Q 8–12 H³⁹ | • Some suggest dogs only  
• Pharmacokinetics, but no clinical data, available |
| Morphine/lidocaine/ketamine CRI | Dogs: Morphine, 4 mcg/kg/min  
Lidocaine, 50 mcg/kg/min  
Ketamine, 10 mcg/kg/min CRI for 24–48 H | • Primary adverse effects include sedation  
• Clinical utility for chronic pain holiday anecdotal only  
• Administer combined or individually |
| Tramadol* | Cats: 1–4 mg/kg PO Q 12 H³⁹  
Dogs: 2–10⁺ mg/kg PO Q 8–12 H³⁹ | • Primary adverse effects include, in humans, GI effects, behavioral changes, seizure potentiation, hypertension, bleeding dyscrasia, sedation  
• Unfavorable pharmacokinetics in dogs; better in cats  
• No safety or toxicity data in dogs or cats; limited to no data to support efficacy in dogs  
• Higher doses may increase risk for adverse effects |
| Venflaxine* (SSNRI) | 3–4 mg/kg PO Q 8–12 H²¹ | • Not in clinical use for chronic pain in dogs or cats  
• No safety or toxicity data |

a. Caution should be exercised when using these and other serotoninergic, monoaminergic drugs in combination.  
b. If used in combination with acetaminophen, base dosage administered on calculated acetaminophen dose.  
c. Higher doses are more likely to lead to adverse effects, and it is prudent to initiate dosing at 2–4 mg/kg.  
NMDA = N-methyl-D-aspartate; SSNRI = serotonin-norepinephrine reuptake inhibitor

lar injection in horses with OA; it suppresses the highly pro-inflammatory cytokine Interleukin-1. There is no similar commercial product for use in dogs, but there is indication that the modality may have a disease-modifying effect in this species.⁴¹

A commercial systemically administered anti-nerve growth factor monoclonal antibody product is currently in development for the treatment of canine OA. Investigations are also in progress for treatment of canine OA with Interleukin-10, a potent inhibitor of spinal cord glial activity.

IN SUMMARY
The ideal pain management protocol for a particular OA patient will vary by stage of disease, doctor and client values, and of course, individual needs and responses.  

COX = cyclooxygenase; CRI = constant rate infusion; DHA = docosahexaenoic acid; EPA = eicosapentaenoic acid; NSAID = nonsteroidal anti-inflammatory drug; OA = osteoarthritis; PSGAG = polysulfated glycosaminoglycan

TABLE 3. Common Nonpharmacologic Therapies for Canine & Feline OA

- Acupuncture  
- Myofascial trigger point therapy  
- Therapeutic laser (photobiomodulation)  
- Pulsed acoustic wave therapy  
- Pulsed electromagnetic field therapy
References


15. Conzenius M. Personal communication 2012.


19. Troncy E. Personal communication, 2013; publication pending.


Mark Epstein, DVM, Diplomate AVBP (Canine/Feline), CVPP, is the senior partner and medical director of Carolinas Animal Pain Management & TotalBond Animal Hospitals, a group of AAHA-accredited practices in the Charlotte and Gastonia, North Carolina, areas. He is a member of the American Academy of Pain Management and International Veterinary Academy of Pain Management, and a past president of the IVAPM and AVBP, and an author and lecturer on the recognition, prevention, and treatment of pain. Dr. Epstein received his DVM from the University of Georgia.